News

Novato, Calif. And New York, NY, December 18, 2019  — Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, and Royalty Pharma today announced that Ultragenyx has sold to Royalty Pharma for $320

Pharmakon Funds to Invest Up to $70 Million in Senior-Secured Loans to Epizyme. Royalty Pharma announced today that it has agreed to pay $330 million to purchase Eisai Co., Ltd.’s royalties on future worldwide sales of tazemetostat, Epizyme Inc.’s (Nasdaq: EPZM) lead investigational agent, outside

NEW YORK, April 1, 2019 – Royalty Pharma and Arteaus Therapeutics, a biotechnology development company co-founded by Atlas Venture and OrbiMed, announced today that Arteaus has sold its royalty interest on future global net sales of Eli Lilly and Company’s (NYSE: LLY) Emgality (galcanezumab), an

Royalty Pharma and Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), a clinical-stage biopharmaceutical company with a portfolio of innovative, late-stage product candidates targeting neurological and neuropsychiatric diseases, including rare disorders, today announced that the company has

Updates 2019 full-year financial guidance Conference call with slides to be held today at 5:00 p.m. Eastern time SAN DIEGO and NEW YORK (March 5, 2019) – Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) and Royalty Pharma  announce the sale of Ligand’s Promacta®-related intellectual property

Royalty Pharma announced today that it has acquired future royalty streams and $85 million of potential commercial milestones on Sanofi’s (NYSE:SNY) Soliqua® 100/33/ Suliqua® and Lyxumia®/Adlyxin® from Zealand Pharma A/S (NASDAQ:ZEAL), for $205 million in cash, to be paid when the transaction

Biohaven And Royalty Pharma Announce Royalty Funding And Stock Purchase Agreements Totaling $150 Million. Royalty Pharma acquires approximately 2% royalty rights on global annual net sales of rimegepant and BHV- 3500 from Biohaven for $100 million. Royalty participation rate subject to reduction to

Royalty Pharma Acquires Royalty Rights on Global Net Sales of Sacituzumab Govitecan (IMMU132) Across All Indications for $175 Million. Royalty Pharma Acquires $75 Million of Immunomedics Common Stock at $17.15 per share, a More Than 15% Premium over 15-Day Moving Average.

Dublin, Ireland and New York, NY (US) – February 27, 2017  — Perrigo Company plc (NYSE; TASE: PRGO) today announced it has signed a definitive agreement to divest its rights to the royalty stream from the global net sales of the multiple sclerosis drug Tysabri® (natalizumab) to Royalty Pharma.

Royalty Pharma Buys 4.5 Percent Royalty on Worldwide Sales for $90 Million Plus $10 Million Equity in Cytokinetics. Cytokinetics Agrees to Exercise Option to Co-Fund Phase 3 Development Program Under Collaboration with Amgen for Increased Royalty and Co-Promotion Rights in North America New York,